IgGenix Announces Presentations on the Future of Food Allergy Treatment at Gordon Research Conference

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–IgGenix, Inc., a preclinical biotechnology company taking a breakthrough approach to directly combating allergic disease, today announced that three presentations will be given by the co-founders of IgGenix at the upcoming Food Allergy Research Conference Gordon to be held November 13-18, 2022, in Oxnard, CA.

“IgGenix is ​​deeply invested in transforming the approach to allergy treatment by paving the way to a molecular understanding of allergic disease,” said IgGenix Co-Founder and Chief Technology Officer Derek Croote, Ph.D. “We look forward to meeting with other leaders in the food allergy community to share how translating our research has the potential to revolutionize the standard of allergy care for the millions of people who suffer from allergic diseases, including me. understood.

Food allergies affect approximately 32 million Americans and 200 million people worldwide, and their incidence is increasing. Every three minutes, someone goes to the emergency room with foodborne anaphylaxis. IgGenix is ​​committed to developing safer treatments with faster onset of action and more sustained clinical response through the redesign of human monoclonal IgE antibodies.

Presentation details:

Climate Change and Health: Problem- and Solution-Oriented Research Approaches

  • Speaker: Kari Nadeau, MD, Ph.D., FAAAAI

  • Date and time: Sunday, November 13, 7:50-8:30 p.m. PT

Single cell genomics and allergies

  • Speaker: Stephen Quake, D. Phil.

  • Date and time: Tuesday, November 15, 11:30 a.m. – 11:55 a.m. PT

Unbiased Human IgE Antibody Discovery Produces High-Affinity Antibodies Against Many Diverse Allergens

  • Speaker: Derek Croote, Ph.D.

  • Date and time: Tuesday, November 15, 8:30 – 8:55 p.m. PT

About IgGenix

IgGenix is ​​a private biotechnology company taking a breakthrough approach to directly treating food allergies and other severe allergies by rearranging key antibodies involved in the allergic cascade. Based on the research of Stanford University Professors Stephen Quake, Kari Nadeau and Derek Croote, IgGenix isolates allergen-specific IgE antibodies using its SEQ SIFTER™ discovery platform. IgGenix then transforms these IgE antibodies into IgG antibodies designed to inhibit the allergic cascade. This new approach can prevent life-threatening allergic reactions, save lives and reduce the constant fear that plagues people with severe allergies. For more information, visit www.IgGenix.com.

Comments are closed.